

Safe prescribing and withdrawal management Committee meeting 8

Date: 30 09 2020

Location: Virtual Meeting: Zoom platform

Minutes: Final

Committee members present:		
Kelly: Deirdre (Chair)		(Present for notes 1 – 8)
Stannard: Cathy (Topic adviser)		(Present for notes 1 – 8)
Buitendach: Mark		(Present for notes 1 – 8)
Davies: Emma		(Present for notes 1 – 8)
Ellis: Benjamin		(Present for notes 1 – 8)
Foell: Jens		(Present for notes 1 – 5)
Montagu: Luke		(Present for notes 1 – 8)
Trewern: Louise		(Present for notes 1 – 8)
Watson: Caroline		(Present for notes 1 – 8)
Ramanuj: Parashar		(Present for notes 1 – 8)
Montagu: Luke		(Present for notes 1 – 8)
In attendance:		
Carville: Serena	NGC, Associate Director, Guideline Lead	(Present for notes 1 – 8)
Clubbe: Richard	NGC, Research Fellow	(Present for notes 1 – 8)
Diaz: Tamara	NGC, Project Manager	(Present for notes 1 – 8)
Mariani: Alfredo	NGC, Health Economist	(Present for notes 1 – 8)
Terrazas-Cruz: Emily	NGC, Senior Research Fellow	(Present for notes 1 – 8)
Vasileiou: Melina	NGC, Research Fellow	(Present for notes 1 – 8)
Keir: Caroline	NICE, Guideline Commissioning Manager	(Present for notes 1 – 8)
Coopteers:		
Andre Geel		(Present for notes 1 – 6)
Observers:		
None		N/A
Apologies:		
Finch: Emily		

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the 8th meeting of the safe prescribing and withdrawal management guideline committee and thanked them for their participation.

The Chair informed the Committee that apologies had been received for Emily Finch (Addiction Psychiatrist).

The Chair outlined the objectives of the meeting, which included: presenting the evidence for the following questions:

- What are the most clinically and cost effective pharmacological and non-pharmacological strategies, for example tapered withdrawal or education and support, for the safe withdrawal of prescribed medicines associated with dependence or withdrawal symptoms (opioids)?
- What is the optimal frequency of review of prescribed medicines associated with dependence or withdrawal symptoms?
- What should be included in a review of prescribed medicines associated with dependence or withdrawal symptoms?

2. Declarations of interest

The Chair invited Committee members to verbally declare any new conflicts that would have arisen since the last meeting. All new declarations have been listed below:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Luke Montague	Lay member	Speaking at Westminster Health Forum conference on prescribed drug dependence. 08 October 2020	Specific non-financial, Professional interest.	Declare and participate
		Contributed to three workshops on patient needs analysis relating to prescribed drug dependence for Cross Party Group for Prescribed Drug Dependence. September 2020.	Specific non-financial, Professional interest.	Declare and participate

		Attended two meetings with NHS England to discuss its Prescribed Drug Oversight Group working with the Cross Party Group for Prescribed Drug Dependence as part of follow-up to PHE report on the topic. July 2020.	Specific non-financial, Professional interest.	Declare and participate
Emma Davies	Pharmacist	Gave written response to pharmaceutical journal on new recommendations on opioids from MHRA – published online on 25 September 2020	Specific, non-financial, Professional interest	Declare and participate
Parashar Ramanuj	Consultant Psychiatrist	Delivered a talk to the Sri Lankan Psychiatric Association Talk entitled: ‘pain for psychiatrists, not all that painful’. Was gifted an M&S hamper, for his participation in the event, this will be donated to a food bank.	Specific, non-financial, Professional interest	Declare and participate

The Chair and a senior member of the Developer’s team noted that the interests declared at previous meetings did not prevent attendees from fully participating in the meeting.

3. Minutes of the previous meeting

The committee agreed that the minutes of GC 07 were an accurate record of the previous virtual meeting.

4. Resource Impact Presentation

Mr. Ian Mather delivered a presentation to the committee on Resource Impact Awareness for NICE guidelines.

5. Evidence review: withdrawal symptoms (opioids)

Melina Vasileiou presented a revised evidence review for the following question: What are the most clinically and cost effective pharmacological and non-pharmacological strategies, for example tapered withdrawal or education and support, for the safe withdrawal of prescribed medicines associated with dependence or withdrawal symptoms (opioids)?

The draft summary of the committee’s discussion, linking the evidence to the recommendations will be completed and circulated for the committee’s review at a later meeting.

6. Evidence reviews: Monitoring

Richard Clubbe presented a revised evidence review for the following questions:

- What is the optimal frequency of review of prescribed medicines associated with dependence or withdrawal symptoms?
- What should be included in a review of prescribed medicines associated with dependence or withdrawal symptoms?

The draft summary of the committee's discussion, linking the evidence to the recommendations will be completed and circulated for the committee's review at a later meeting.

7. Any other business

There being no further business the meeting ended at 1515.

Date of next meeting: 10 November 2020

Location of next meeting: Zoom Virtual Meeting Platform